FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia - FDA Press Releases

The U.S. Food and Drug Administration today approved Vyxeos for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of chemotherapy drugs daunorubicin and cytarabine.

from Food and Drug Administration--Press Releases http://ift.tt/2vwf3K9
via IFTTT